Viromids: A Redosable Gene-Delivery Platform for Ocular Therapy

CEVR
Overview

Viromids are next-generation gene delivery vectors inspired by the human virome. They enable repeat dosing, delivery of large genes, and lower manufacturing costs while maintaining exceptional purity and safety.

  • Viromids: A Redosable Gene-Delivery Platform for Ocular Therapy
Problem addressed

To overcome the bottlenecks of current viral vectors, such as immune barriers preventing redosing and high costs, Viromids enables safe, repeatable, and affordable ocular treatments for patients everywhere.

Innovation
  • iPhagemids: Derived from filamentous bacteriophages; well-tolerated, non-inflammatory, and customizable for large genetic cargos.
  • Anellomids: Based on ubiquitous, non-pathogenic anelloviruses that offer lifelong immune tolerance, making them ideal for repeat dosing.
Key impact
  • Redosable delivery and broader eligibility: Overcomes immune barriers to allow for repeat dosing and access for more patients.
  • Expanded payload capacity: Able to deliver larger or multiple genes compared to traditional vectors.
  • Ultra-low-cost manufacturing: Uses simple fermentation-based scalability to improve global accessibility and equity.
Award
  • Grand Award at the 2025 Asia Exhibition of Innovations and Inventions Hong Kong
  • Gold Medal with congratulations of Jury at the 2025 Asia Exhibition of Innovations and Inventions Hong Kong
  • Gold Medal with congratulations of Jury at the 51st International Exhitbition on Inventions Geneva
  • Special Prize of “ LUCIAN BLAGA” University of SIBIU, ROMANIA at the 51st International Exhitbition on Inventions Geneva
Application
  • Precision genetic medicine for ocular diseases
  • Large-gene therapy and multi-gene delivery

The Centre for Eye and Vision Research (CEVR)  is a research collaboration between The Hong Kong Polytechnic University and the University of Waterloo in Canada under the InnoHK initiative of the HKSAR Government. It is located at the Hong Kong Science Park, Shatin, Hong Kong. It is the first global hub performing ground-breaking research in five key areas Myopia and Eye Growth, Ocular Drug Discovery and Delivery, Vision Enhancement, Tear Film and Ocular Surface, and Advanced Optometric Technology. The mission of CEVR is to generate technologies to prevent vision loss in the aging population and preserve healthy vision.

Enquiry